# Open-label, Pilot Protocol of Patients With Rheumatoid Arthritis Who Switch to Infliximab After Incomplete Response to Etanercept

> **NCT00317538** · PHASE3 · COMPLETED · sponsor: **Centocor Ortho Biotech Services, L.L.C.** · enrollment: 28 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** infliximab, etanercept

## Key facts

- **NCT ID:** NCT00317538
- **Lead sponsor:** Centocor Ortho Biotech Services, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** —
- **Final completion:** 2004-11
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2011-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00317538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00317538, "Open-label, Pilot Protocol of Patients With Rheumatoid Arthritis Who Switch to Infliximab After Incomplete Response to Etanercept". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00317538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*